INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Tempus AI, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit – TEM

Core Viewpoint - The Tempus AI class action lawsuit alleges that the company and its executives made misleading statements and failed to disclose critical information that inflated the company's stock value during the specified class period [3][4]. Group 1: Class Action Details - The class action lawsuit is titled Shouse v. Tempus AI, Inc., and it allows purchasers of Tempus AI common stock from August 6, 2024, to May 27, 2025, to seek appointment as lead plaintiff by August 12, 2025 [1]. - The lawsuit claims violations of the Securities Exchange Act of 1934 by Tempus AI and certain executives [1]. Group 2: Allegations Against Tempus AI - Allegations include that Tempus AI inflated contract values, many of which were with related parties and included non-binding opt-ins [3]. - Concerns were raised about the credibility of Tempus AI's joint venture with SoftBank, suggesting it created an appearance of "round-tripping" capital [3]. - The business model of Ambry Genetics Corporation, acquired by Tempus AI, is criticized for aggressive and potentially unethical billing practices [3]. - AstraZeneca's reduced financial commitments to Tempus AI through a questionable "pass-through payment" is also highlighted [3]. - These issues indicate weaknesses in Tempus AI's core operations and revenue prospects [3]. Group 3: Impact on Stock Price - Following a research report from Spruce Point Capital Management on May 28, 2025, which raised concerns about Tempus AI's management and financial reporting, the company's stock price fell by more than 19% [4].